[go: up one dir, main page]

AR082435A1 - Valsartan altamente cristalino - Google Patents

Valsartan altamente cristalino

Info

Publication number
AR082435A1
AR082435A1 ARP110102771A ARP110102771A AR082435A1 AR 082435 A1 AR082435 A1 AR 082435A1 AR P110102771 A ARP110102771 A AR P110102771A AR P110102771 A ARP110102771 A AR P110102771A AR 082435 A1 AR082435 A1 AR 082435A1
Authority
AR
Argentina
Prior art keywords
valsartan
crystalline form
highly crystalline
highly
degrees
Prior art date
Application number
ARP110102771A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR082435A1 publication Critical patent/AR082435A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una forma altamente cristalina de valsartan, composiciones farmacéuticas de la misma, y un proceso para la preparación de las mismas.Reivindicación 1: Una forma altamente cristalina de valsartan, caracterizada por un patrón de difracción en polvo de rayos-X con un pico a aproximadamente 31.0 ± 0.2 grados 2-q, y que carece sustancialmente de picos de difracción de rayos-X entre 0 y 8 ± 0.2 grados 2-q. Reivindicación 3: Una forma altamente cristalina de valsartan que tiene una sola estructura cristalina definida por las siguientes posiciones de picos: @@@@@@@@@
ARP110102771A 2010-08-03 2011-08-01 Valsartan altamente cristalino AR082435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37028510P 2010-08-03 2010-08-03

Publications (1)

Publication Number Publication Date
AR082435A1 true AR082435A1 (es) 2012-12-05

Family

ID=44645072

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102771A AR082435A1 (es) 2010-08-03 2011-08-01 Valsartan altamente cristalino

Country Status (19)

Country Link
US (1) US20130137737A1 (es)
EP (1) EP2601180A1 (es)
JP (1) JP2013532707A (es)
KR (1) KR20130139863A (es)
CN (1) CN103052630A (es)
AR (1) AR082435A1 (es)
AU (1) AU2011287616A1 (es)
BR (1) BR112013002589A2 (es)
CA (1) CA2806657A1 (es)
CL (1) CL2013000335A1 (es)
CO (1) CO6670580A2 (es)
EC (1) ECSP13012459A (es)
MA (1) MA34580B1 (es)
MX (1) MX2013001251A (es)
PH (1) PH12013500210A1 (es)
RU (1) RU2013109365A (es)
SG (1) SG187007A1 (es)
TW (1) TW201206428A (es)
WO (1) WO2012016969A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739564A (zh) * 2012-02-20 2014-04-23 中国科学院上海药物研究所 缬沙坦的多晶型及其制备方法
CN103435567B (zh) * 2013-09-09 2015-08-26 山东新华制药股份有限公司 缬沙坦的精制方法
CN105801506A (zh) * 2014-12-30 2016-07-27 天津法莫西医药科技有限公司 缬沙坦新晶型及其制备方法
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
CN105777660A (zh) * 2016-03-29 2016-07-20 潍坊盛瑜药业有限公司 缬沙坦晶型e的诱导结晶工艺及应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30484A (en) 1990-02-19 1997-05-28 Ciba Geigy Acy compounds pharmaceutical composition containing said compound and method of use thereof
CN1137887C (zh) * 2000-04-07 2004-02-11 常州四药制药有限公司 一种合成缬沙坦的改进方法
MXPA03000525A (es) 2000-07-19 2003-05-14 Novartis Ag Sales de valsartan.
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (en) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
CN1788004A (zh) * 2003-03-17 2006-06-14 特瓦制药工业有限公司 缬沙坦的多晶型
CZ298685B6 (cs) * 2003-05-15 2007-12-19 Zentiva, A.S. Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu)
ITMI20032267A1 (it) * 2003-11-21 2005-05-22 Dinamite Dipharma S P A In Forma A Bbreviata Diph Procdimento per la preparzione di valsartan e suoi intermedi
CN101103006A (zh) 2005-01-11 2008-01-09 特瓦制药工业有限公司 无定形缬沙坦的制备方法
WO2007017897A2 (en) 2005-05-25 2007-02-15 Ipca Laboratories Ltd. Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
ITMI20051989A1 (it) * 2005-10-20 2007-04-21 Dipharma Spa Procedimerntyo per la preparazione di composti antagonisti di angiotensina ii
WO2007069271A2 (en) * 2005-10-31 2007-06-21 Alembic Limited Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan)
CN1844110B (zh) * 2005-12-09 2010-07-14 浙江天宇药业有限公司 高光学纯度的缬沙坦的合成方法
CN101270096B (zh) * 2007-03-22 2011-08-03 浙江华海药业股份有限公司 一种合成缬沙坦的方法
CN100522953C (zh) * 2007-04-03 2009-08-05 浙江天宇药业有限公司 一种缬沙坦的新合成方法
ES2316281B1 (es) * 2007-05-14 2010-02-09 Quimica Sintetica, S.A. Procedimiento para la preparacion de valsartan.
CN101362728B (zh) * 2008-08-22 2011-07-20 北京赛科药业有限责任公司 一种缬沙坦的合成方法
CN101768128B (zh) * 2009-01-05 2012-10-10 浙江华海药业股份有限公司 一种含10%以上异构体的缬沙坦的精制方法
CN101475540B (zh) * 2009-01-22 2011-05-11 江苏德峰药业有限公司 一种缬沙坦的制备方法
CN101735164A (zh) * 2009-12-22 2010-06-16 北京赛科药业有限责任公司 缬沙坦中杂质f的研究及控制方法

Also Published As

Publication number Publication date
TW201206428A (en) 2012-02-16
MX2013001251A (es) 2013-03-18
WO2012016969A1 (en) 2012-02-09
PH12013500210A1 (en) 2020-10-19
RU2013109365A (ru) 2014-09-10
SG187007A1 (en) 2013-02-28
JP2013532707A (ja) 2013-08-19
CN103052630A (zh) 2013-04-17
CO6670580A2 (es) 2013-05-15
KR20130139863A (ko) 2013-12-23
CL2013000335A1 (es) 2013-06-14
ECSP13012459A (es) 2013-03-28
EP2601180A1 (en) 2013-06-12
CA2806657A1 (en) 2012-02-09
MA34580B1 (fr) 2013-10-02
BR112013002589A2 (pt) 2019-09-24
US20130137737A1 (en) 2013-05-30
AU2011287616A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
CR20110457A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma
BR112014010433A2 (pt) método e máquina para produzir uma cápsula de uso único para bebidas e cápsula obtida com o método
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
BR112013019223A2 (pt) forma de dosagem para liberação modificada, processo para a fabricação de um comprimido e processo para a fabricação de uma forma de dosagem oral
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
EP2665471A2 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
AR082435A1 (es) Valsartan altamente cristalino
WO2014153495A9 (en) Novel stat3 inhibitors
EP3251696A4 (en) Transdermally absorbable base material comprising lipid peptide-type compound
PH12015502122A1 (en) Sovaprevir polymorphs and methods of manufacturing thereof
AR101368A1 (es) Forma cristalina de sofosbuvir y proceso para su preparación
AR076856A1 (es) Lenalidomida polimorfa y proceso para su preparacion
IN2012DN04868A (es)
ES2650604T3 (es) Nueva forma cristalina VII de agomelatina, método de preparación y utilización de la misma, así como composición farmacéutica que la contiene
TR201000685A2 (tr) Salmeterol ve flutikazon içeren farmasötik preparatlar.
ES2489467T3 (es) Polimorfo novedoso del clorhidrato del éster (6-dimetilaminometil-2-naftalenílico) del ácido (4-hidroxicarbamoilfenil)-carbámico
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
ES2492673T3 (es) Formas cristalinas de un ingrediente farmacéutico activo
AR107441A1 (es) Forma cristalina de cobicistat

Legal Events

Date Code Title Description
FB Suspension of granting procedure